Roivant Sciences Ltd. (ROIV)
| Market Cap | 26.42B +155.0% |
| Revenue (ttm) | 7.53M -67.6% |
| Net Income | -266.25M |
| EPS | -0.49 |
| Shares Out | 722.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,282,288 |
| Open | 36.77 |
| Previous Close | 36.50 |
| Day's Range | 36.23 - 36.96 |
| 52-Week Range | 14.93 - 42.50 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 48.08 (+31.47%) |
| Est. Earnings | Nov 9, 2026 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rh... [Read more]
Financial Performance
In fiscal year 2026, Roivant Sciences's revenue was $8.26 million, a decrease of -71.57% compared to the previous year's $29.05 million. Losses were -$299.77 million, 74.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $48.08, which is an increase of 31.47% from the latest price.
News
Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback
H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity ...
Roivant Sciences price target raised to $41 from $37.50 at BofA
BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and keeps a Neutral rating on the shares after having hosted CEO Matt…
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Roivant Sciences Transcript: Bank of America Global Healthcare Conference
Recent milestones include positive phase II data for mosliciguat and the launch of LISRAYA in dermatomyositis, with more clinical readouts expected soon. Focus is on commercialization, expanding indications, and advancing FcRn programs, especially in autoimmune and orphan diseases like Graves' disease and non-infectious uveitis.
Roivant Sciences initiated with a Buy at Stifel
Stifel initiated coverage of Roivant Sciences (ROIV) with a Buy rating and $51 price target The company offers a “compelling multi-asset story with scarcity value” within the specialty autoimmune and…
Roivant Sciences Transcript: Citigroup’s Biopharma Back to School Summit 2026
Significant clinical and financial progress was highlighted, including FDA approval for brepocitinib, best-in-class data for mosliciguat in PH-ILD, and strong efficacy for IMVT-1402 in RA. Multiple late-stage readouts and launches are expected in the coming year.
Roivant Sciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Mosliciguat delivered record efficacy in pulmonary hypertension, prompting plans for broader indications and rapid phase III enrollment. Brepocitinib's DM launch is progressing steadily, with strong physician enthusiasm and significant market potential. Key pipeline catalysts include NIU and RA data, while the company maintains a flexible, value-focused corporate structure.
Roivant Sciences price target raised to $55 from $50 at TD Cowen
TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $55 from $50 and keeps a Buy rating on the shares. The firm updated its model following the…
Roivant Sciences price target raised to $46 from $42 at Guggenheim
Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $46 from $42 and keeps a Buy rating on the shares, telling investors that Phase 2 PHocus data for…
Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $47 from $41 and keeps a Buy rating on the shares. The firm believes mosliciguat’s results strengthen Roivant’s…
Roivant Sciences rises 18.9%
Roivant Sciences (ROIV) is up 18.9%, or $6.60 to $41.53.
Roivant Sciences price target raised to $52 from $42 at Jefferies
Jefferies raised the firm’s price target on Roivant Sciences (ROIV) to $52 from $42 and keeps a Buy rating on the shares after the company reported “strong” data from its…
Roivant Sciences Transcript: Wells Fargo 21st Annual Healthcare Conference
PHocus phase IIb data in PH-ILD showed unprecedented efficacy and safety, prompting rapid phase III enrollment. LISRAYA launched for dermatomyositis with strong uptake and steroid-sparing benefits. The FcRn pipeline advances in multiple autoimmune indications, with key data readouts and regulatory milestones expected over the next 12–18 months.
Roivant Sciences rises 17.6%
Roivant Sciences (ROIV) is up 17.6%, or $6.15 to $41.08.
Roivant Sciences Transcript: Study result
The PHocus study in PH-ILD showed mosliciguat achieved a record 56.3% reduction in PVR, significant improvements in six-minute walk and NT-proBNP, and a favorable safety profile. Benefits were consistent across subgroups, and a phase III trial is underway to confirm these results.
Roivant Sciences Press release: Study result
Roivant Sciences issued a press release on September 8, 2026, disclosing material business information to investors.
Roivant Sciences Slides: Study result
Roivant Sciences has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Roivant's experimental lung disease drug meets goals in mid-stage study
Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in prem...
Roivant Sciences up 21% to $42.50 after Phase 2 PHocus trial met endpoint
06:13 EDT Roivant Sciences (ROIV) up 21% to $42.50 after Phase 2 PHocus trial met endpoint
Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial
Roivant announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progr...
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROI...
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for...
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patient...
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROI...